Posted by Michael Wonder on 20 Feb 2024
Disc Medicine receives FDA fast track designation for DISC-0974 for the treatment of anaemia in non-dialysis dependent chronic kidney disease
20 February 2024 - Disc Medicine today announced that the US FDA has granted fast track designation to DISC-0974 for the treatment of patients with non-dialysis dependent chronic kidney disease and anaemia.
DISC-0974 is an investigational monoclonal antibody targeting a BMP-signaling co-receptor called haemojuvelin and is designed to suppress hepcidin production and increase serum iron levels in patients suffering from anaemia of inflammation.
